Abstract
BACKGROUND: Carboplatin is used to treat gynecologic cancers. Reexposure to carboplatin in the recurrent disease setting increases the risk of hypersensitivity reactions, which can be mild or cause death. A carboplatin desensitization protocol was developed to help with patient tolerance, but no standard protocol existed. OBJECTIVES: This protocol was updated to replace an older desensitization protocol, align with best practices, and bring cost savings to the institution through reduced labor and shortened hospital stays. METHODS: The updated four-bag, four-hour protocol was implemented in patient care on March 8, 2024. A total of five desensitizations were completed. Each desensitization was retrospectively reviewed and assessed for safety and tolerability using the Common Terminology Criteria for Adverse Events. FINDINGS: Five desensitizations successfully occurred for two patients between March 8 and July 13, 2024. Each desensitization saved $108 in pharmacy supply costs and $92 in pharmacy labor costs. Saved nursing costs totaled about $400 for each desensitization.